Taking A Bold Path To Improve Fibrosis Prognosis

Agomab Is Targeting Two Growth Factor Pathways Which Could Help To Modify Disease Outcomes

 
• By Chloe Kent

Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.  

Fibrosis
• Source: Shutterstock

Rising Leaders Home

Fibrotic processes are the root cause behind a variety of hard-to-treat diseases, and are key to the scientific approach used by Agomab Therapeutics NV, a Belgian biotech which aims to preserve and restore

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rising Leaders

More from Leadership